Trial Profile

Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jun 2021 Planned End Date changed from 1 Mar 2026 to 1 Mar 2029.
08 Jun 2021 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2027.
25 Sep 2020 Protocol amended to treatment to include dose for adult: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks Children and Adolescents weighing less than 40 kg: 3 mg/kg IV over 30 minutes every 2 weeks, eligibility criteria amended to include patients upto age 50.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com